Parp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1] [@am2004]
PARP2 (Poly(ADP-Ribose) Polymerase 2) is a gene encoding a member of the PARP family involved in DNA repair, genomic stability, and cellular stress responses. [2] [@wang2023]
Parp2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1] [@am2004]
PARP2 (Poly(ADP-Ribose) Polymerase 2) is a gene encoding a member of the PARP family involved in DNA repair, genomic stability, and cellular stress responses. [2] [@wang2023]
Overview
Mermaid diagram (expand to render)
PARP2 encodes Poly(ADP-Ribose) Polymerase 2, a nuclear enzyme that catalyzes poly(ADP-ribosyl)ation in response to DNA damage. It is the second most abundant PARP enzyme after PARP1 and plays critical roles in single-strand break repair, base excision repair, and regulation of chromatin structure. PARP2 is expressed in most tissues, with high expression in brain regions including the hippocampus, [cortex](/brain-regions/cortex), and cerebellum, where it supports neuronal genomic integrity. [3] [@fouquerel2020]
Gene Structure
The PARP2 gene is located on chromosome 14q13.2 and consists of multiple exons encoding a protein of approximately 583 amino acids. The gene shares structural similarities with PARP1, with distinct regulatory domains that confer unique functions. [4] [@ishiyama2021]
Exon Organization
Exon 1: 5' UTR and start codon
Exons 2-10: Coding sequence
Exon 11: 3' UTR with polyadenylation signal
Molecular Function
DNA Damage Recognition
Recognizes DNA single-strand breaks and base lesions
Binds to damaged DNA through zinc-finger domains
Rapid recruitment to sites of DNA damage
Poly(ADP-Ribosyl)ation Catalysis
Uses NAD+ as substrate to synthesize poly(ADP-ribose) polymers
Auto-modification after DNA damage detection
Creates docking sites for DNA repair proteins
DNA Repair Recruitment
Recruits XRCC1, ligase III, and DNA polymerase β
Facilitates single-strand break repair
Works with PARP1 in overlapping pathways
Expression Pattern
Brain Expression
[Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 regions and dentate gyrus
Cerebral cortex: Moderate expression across layers
Cerebellum: Expression in Purkinje cells and granule cells
Substantia nigra: Dopaminergic [neurons](/entities/neurons) show PARP2 expression
[Astrocytes](/entities/astrocytes) and [microglia](/entities/microglia): Cell-type specific expression
Peripheral Tissues
Testis and ovary: Highest expression
Heart and skeletal muscle: Moderate expression
Liver and kidney: Lower expression
Disease Associations
Alzheimer's Disease
PARP2 hyperactivation in AD brains leads to NAD+ depletion
Excessive PARylation contributes to bioenergetic crisis
DNA damage accumulation in neurons with age
PARP inhibitors show neuroprotective potential in models
Relationship between PARP activation and [tau](/proteins/tau) pathology
Parkinson's Disease
PARP activation in dopaminergic neurons (SNc)
DNA damage accumulation contributes to neuronal loss
6-OHDA and MPTP models show PARP involvement
PARP1/PARP2 double knockout more vulnerable to PD models
NAD+ restoration strategies as therapeutic approach
Amyotrophic Lateral Sclerosis (ALS)
PARP activation in motor neurons
DNA damage stress in ALS pathogenesis
SOD1 and [C9orf72](/entities/c9orf72) models show PARP involvement
PARP inhibitors in preclinical testing
Huntington's Disease
Mutant [huntingtin](/proteins/huntingtin-protein) causes DNA damage
PARP activation contributes to neuronal dysfunction
Therapeutic targeting of PARP in HD
Stroke and Ischemia
PARP activation in ischemic penumbra
NAD+ depletion worsens outcomes
PARP inhibitors in stroke models show benefit
Therapeutic Implications
PARP Inhibitors
Olaparib: FDA-approved for cancer, being explored for neurodegeneration
Niraparib: Being investigated for neuroprotection
Rucaparib: Shows promise in preclinical models
NAD+ Boosters
Nicotinamide riboside (NR) to restore NAD+
Nicotinamide mononucleotide (NMN)
Combination approaches with PARP inhibition
Gene Therapy
Viral vector-mediated PARP2 modulation
Targeting specific neuronal populations
Clinical Trials
While no PARP inhibitors are FDA-approved specifically for neurodegenerative diseases, several clinical trials are investigating: [5] [@sznt2021]
NAD+ precursors for age-related cognitive decline
Combination approaches targeting DNA repair
Biomarker studies measuring PARylation levels
Animal Models
PARP2 knockout mice: Viable with subtle DNA repair deficits
PARP1/PARP2 double knockout: Embryonic lethal
Conditional knockout: Brain-specific models for neurodegeneration studies
Transgenic models: Overexpression of PARP2
Research Directions
Development of brain-penetrant PARP inhibitors
Biomarker development for PARP activation
Combination therapies targeting multiple pathways
Understanding PARP2 vs PARP1 specificity
Background
The study of Parp2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [6] [@martire2020]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [7] [@blennow2022]